Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Lin, Yuan ^a   Xiao, Ye Cheng ^b   Zhu, Hong ^b   Xu, Qing Yan ^a   Qi, Lei ^a   Wang, Yu Bin ^a   Li, Xiu Juan ^a   Zheng, Ma Li ^a   Zhong, Rui Sheng ^a   Zhang, Yi ^b   Xu, Xiang Dong ^b   Wu, Bo Le ^b   Xu, Zhu Mei ^b   Lu, Xiang Hong ^b  

^a Xiamen Hospital of Traditional Chinese Medicine   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; CELL PROLIFERATION; CHINA; COMPARATIVE STUDY; INSULIN RESISTANCE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; SEVERITY OF ILLNESS INDEX; UPREGULATION;

AGED; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHINA; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FIBROBLAST GROWTH FACTORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RETINA; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84900319471     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/929756     Document Type: Article

References (31)

1. Morello C. M., Etiology and natural history of diabetic retinopathy: an overview. American Journal of Health-System Pharmacy 2007 64 17 S3 S7 2-s2.0-35348940263 10.2146/ajhp070330 (Pubitemid 350202222)
2. Song M. K., Roufogalis B. D., Huang T. H. W., Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR- γ -related pharmacology. British Journal of Pharmacology 2012 165 1 4 19 2-s2.0-82955173782 10.1111/j.1476-5381.2011.01411.x
3. Crawford T. N., Alfaro D. V. III, Kerrison J. B., Jablon E. P., Diabetic retinopathy and angiogenesis. Current Diabetes Reviews 2009 5 1 8 13 2-s2.0-65549111100 10.2174/157339909787314149
4. Varma R., Choudhury F., Klein R., Chung J., Torres M., Azen S. P., Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. American Journal of Ophthalmology 2010 149 5 752 761.e3 2-s2.0-77950810564 10.1016/j.ajo.2009.11.014
5. Harris Nwanyanwu K., Talwar N., Gardner T. W., Wrobel J. S., Herman W. H., Stein J. D., Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013 36 6 1562 1568 10.2337/dc12-0790
6. Davidovic S. P., Nikolic S. V., Curic N. J., Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. European Journal of Ophthalmology 2012 22 5 792 798 10.5301/ejo.5000118
7. Gündüz K., Bakri S. J., Management of proliferative diabetic retinopathy. Comprehensive Ophthalmology Update 2007 8 5 245 256 2-s2.0-40949105216
8. Abbate M., Cravedi P., Iliev I., Remuzzi G., Ruggenenti P., Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. Current Diabetes Reviews 2011 7 3 190 200 2-s2.0-79959344912 10.2174/157339911795843168
9. Abhary S., Burdon K. P., Gupta A., Lake S., Selva D., Petrovsky N., Craig J. E., Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Investigative Ophthalmology and Visual Science 2009 50 12 5552 5558 2-s2.0-73349129376 10.1167/iovs.09-3694
10. Ruberte J., Ayuso E., Navarro M., Carretero A., Nacher V., Haurigot V., George M., Llombart C., Casellas A., Costa C., Bosch A., Bosch F., Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. Journal of Clinical Investigation 2004 113 8 1149 1157 2-s2.0-11144354304 10.1172/JCI200419478 (Pubitemid 38544100)
11. Praidou A., Papakonstantinou E., Androudi S., Georgiadis N., Karakiulakis G., Dimitrakos S., Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmologica 2011 89 3 248 254 2-s2.0-79955015955 10.1111/j.1755-3768.2009.01661.x
12. Zakareia F. A., Alderees A. A., Al Regaiy K. A., Alrouq F. A., Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. Journal of Diabetes and Its Complications 2010 24 3 179 185 2-s2.0-77953132225 10.1016/j.jdiacomp.2008.12.007
13. Belov A. A., Mohammadi M., Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harbor Perspectives in Biology 2013 5 6 a015958 10.1101/cshperspect.a015958
14. Canto C., Auwerx J., Cell biology. FGF21 takes a fat bite. Science 2012 336 6082 675 676 10.1126/science.1222646
15. Smith R., Duguay A., Weiszmann J., A novel approach to improve the function of FGF21. BioDrugs 2013 27 2 159 166 10.1007/s40259-013-0013-x
16. Xiao Y., Xu A., Law L. S. C., Chen C., Li H., Li X., Yang L., Liu S., Zhou Z., Lam K. S. L., Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. Journal of Clinical Endocrinology and Metabolism 2012 97 1 E54 E58 2-s2.0-84855498491 10.1210/jc.2011-1930
17. Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D.-S., Mehrbod F., Jaskunas S. R., Shanafelt A. B., FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 6 1627 1635 2-s2.0-20444435873 10.1172/JCI23606 (Pubitemid 40814671)
18. Lin Z., Gong Q., Wu C., Dynamic change of serum FGF21 levels in response to glucose challenge in human. The Journal of Clinical Endocrinology and Metabolism 2012 97 7 E1224 E1228
19. Pyörälä M., Miettinen H., Halonen P., Laakso M., Pyörälä K., Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 2 538 544 2-s2.0-0343485089 (Pubitemid 30086114)
20. Tomić M., Ljubić S., Kastelan S., The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy. Collegium Antropologicum 2013 37 supplement 1 51 57
21. Yamamoto Y., Hirose H., Saito I., Tomita M., Taniyama M., Matsubara K., Okazaki Y., Ishii T., Nishikai K., Saruta T., Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clinical Science 2002 103 2 137 142 2-s2.0-0036349010
22. Muni R. H., Kohly R. P., Lee E. Q., Manson J. E., Semba R. D., Schaumberg D. A., Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmology 2013 131 4 514 521 10.1001/jamaophthalmol.2013.2299
23. Adams A. C., Kharitonenkov A., FGF21: the center of a transcriptional nexus in metabolic regulation. Current Diabetes Reviews 2012 8 4 285 293
24. Stein S., Stepan H., Kratzsch J., Verlohren M., Verlohren H.-J., Drynda K., Lössner U., Blüher M., Stumvoll M., Fasshauer M., Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010 59 1 33 37 2-s2.0-72049097133 10.1016/j.metabol.2009.07.003
25. Murata Y., Konishi M., Itoh N., Fgf21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. Journal of Nutrition and Metabolism 2011 2011 8 10.1155/2011/981315 981315
26. Holland W. L., Adams A. C., Brozinick J. T., An FGF21-adiponectin- ceramide axis controls energy expenditure and insulin action in mice. Cell Metabolism 2013 17 5 790 797 10.1016/j.cmet.2013.03.019
27. Lin Z., Tian H., Lam K. S., Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metabolismolism 2013 17 5 779 789 10.1016/j.cmet.2013.04.005
28. Raz I., Gallwitz B., The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue. Review of Diabetic Studies 2011 8 3 288 292 2-s2.0-84856016128 10.1900/RDS.2011.8.288
29. Abcouwer S. F., Angiogenic factors and cytokines in diabetic retinopathy. Journal of Clinical & Cellular Immunology 2013 supplement 1 11 10.4172/2155-9899
30. Zhou J., Wang S., Xia X., Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Current Eye Research 2012 37 5 416 420 2-s2.0-84859891447 10.3109/02713683.2012.661114
31. Simo R., Roy S., Behar-Cohen F., Keech A., Mitchell P., Wong T. Y., Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Current Medicinal Chemistry 2013 20 26 3258 3266